Company / Gross Margin
United Therapeutics Gross Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
87.9%
FY2025
5-year range
87.9% / 92.7%
FY2021-FY2025
Trend
-1.5%
vs FY2024
Sector context
#4 of 28
Health Care
What the data says
United Therapeutics's gross margin of 87.9% is higher than 86% of companies in the Health Care sector (FY2025). Gross Margin has fluctuated over the past 10 years, ranging from 20.6% in FY2018 to 92.7% in FY2021.
Based on SEC 10-K filings.
87.9% in FY2025 with a 5-year CAGR of -4.8%. Top quartile in the Health Care sector.
Remained stable around 87.9% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -4.2pp
- 5-Year Change
- -4.8pp
- 10-Year Change
- -
Sector benchmark
Top 14% in Health CareTop 14% of 28This company 87.9% Sector average 60.3%
▼
+45.8% above sector average
Key checks
Key Insights
- In FY2025, gross margin decreased 1.5% year-over-year.
- Currently 27.6pp above the Health Care sector average.
- Peak gross margin was recorded in FY2021.
- Lowest gross margin in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 87.9% | -1.5% |
| FY2024 | 89.2% | +0.3% |
| FY2023 | 88.9% | -3.5% |
| FY2022 | 92.2% | -0.6% |
| FY2021 | 92.7% | +0.0% |
| FY2020 | 92.7% | +0.9% |
| FY2019 | 91.9% | +345.2% |
| FY2018 | 20.6% | -15.1% |
| FY2017 | 24.3% | +5.5% |
| FY2016 | 23.0% | +10.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026